1009303-74-5

Basic information

• Product Name: (S)-(5-(2-chloro-4-(3-methylmorpholinyl)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol
• Synonyms: (S)-(5-(2-chloro-4-(3-methylmorpholinyl)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol
• CAS NO: 1009303-74-5
• Molecular Weight: 400.865
• Mol File: 1009303-74-5.mol

Chemical Properties

• CAS DataBase Reference: (S)-(5-(2-chloro-4-(3-methylmorpholinyl)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-(5-(2-chloro-4-(3-methylmorpholinyl)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol(1009303-74-5)
• EPA Substance Registry System: (S)-(5-(2-chloro-4-(3-methylmorpholinyl)pyrido[2,3-d]pyrimidin-7-yl)-2-methoxyphenyl)methanol(1009303-74-5)

Safety Data

• Hazardous Substances Data: 1009303-74-5(Hazardous Substances Data)

Upstream product

• 938443-20-0 2,4,7-trichloropyrido[2,3-d]pyrimidine 
• 938443-19-7 7-chloropyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
• 64321-24-0 2-amino-6-chloro-pyridine-3-carboxamide 
• 58584-92-2 2-amino-6-chloronicotinic acid 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 1009303-42-7 (S)-4-(2,7-dichloropyrido[2,3-d]pyrimidin-4-yl)-3-methylmorpholine 
• 908142-03-0 (3-(hydroxymethyl)-4-methoxy)phenylboronic acid 

Downstream Products

• 1421357-83-6 (S)-(2-methoxy-5-(4-(3-methylmorpholine)-2-(tetrahydro-2H-pyran-4-yl)pyrido[2,3-d]pyrimidin-7-yl)phenyl)methanol 
• 1421357-84-7 (S)-(5-(2-(3,6-dihydro-2H-pyran-4-yl)-4-(3-methylmorpholinyl)pyrido[2,3-d]pyrimidine-7-yl)2-methoxyphenyl)methanol 

Relevant articles and documents

PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS

Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.

COMBINATION 059

This invention relates to a combination product, as defined herein, comprising a MEK inhibitor and a mTOR-selective inhibitor, and to methods for the production of an anti-cancer effect in a patient, which is accordingly useful in the treatment of cancer in a patient. More specifically the present invention relates to; a combination product, as defined herein, comprising a MEK inhibitor and a mTOR-selective inhibitor; a combination product, as defined herein, comprising a kit of parts comprising a MEK inhibitor and a mTOR-selective inhibitor; use of the combination product, as defined herein, in the treatment of cancer; a method of treating cancer comprising administering the combination product, as defined herein, to a patient. The combination product, as defined herein, and methods of the invention are also useful in the treatment of other diseases associated with the activity of MEK, and/or mTOR.

2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS

There is provided a compound of Formula (I), or a pharmaceutically acceptable salt thereof. There are also provided processes for the manufacture of a compound of Formula (1), and the use of a compound of Formula (1) as a medicament and in the treatment of cancer